Identify novel targets with strong genetic evidence
Validate candidate targets or biomarkers and focus investment
Design better studies and enrolment criteria by identifying relevant sub-populations
Discover novel biomarkers that enable higher resolution disease stratification
Genuity Science brings purpose-driven data and genomic know-how to catalyze insights and drive better drug discovery decisions.
We combine retrospective and prospective population-based disease-specific datasets powered for statistical significance to create a robust picture of disease providing stronger signals for clearer conclusions.
Our high-quality whole genome sequence approach is coupled with deep phenotypic data fuelling our advanced analysis - taking insight a step further.
Our expertise in massive, population-scale datasets and deep learning methods is enhanced by expertise in the industry’s only data analysis platform built for population-scale genomics.
Longitudinal insight illuminates disease progression over time for a more comprehensive picture of the disease.
Ionis Pharmaceuticals and Genuity Science have partnered on the discovery of up to 20 novel targets rooted in the underlying biology of a range of diseases.
“I’m convinced that the way Genuity Science is working is the future of genomic research.”
Hear from Leo Saheljio, MD, VP of Translational Medicine on the announcement of the collaboration, and why Ionis chose Genuity Science as a partner for this work.